KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to -$569.9 million.

  • Jazz Pharmaceuticals' Retained Earnings fell 16087.15% to -$569.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$569.9 million, marking a year-over-year decrease of 16087.15%. This contributed to the annual value of $1.1 billion for FY2024, which is 2830.36% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Retained Earnings stood at -$569.9 million for Q3 2025, which was down 16087.15% from -$485.8 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Retained Earnings peaked at $1.3 billion during Q1 2021, and registered a low of -$1.6 billion during Q3 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' median Retained Earnings value was -$485.8 million (recorded in 2025), while the average stood at -$38.2 million.
  • In the last 5 years, Jazz Pharmaceuticals' Retained Earnings plummeted by 28688.64% in 2022 and then soared by 21727.26% in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Retained Earnings (Quarter) stood at $830.2 million in 2021, then crashed by 235.57% to -$1.1 billion in 2022, then skyrocketed by 178.07% to $878.7 million in 2023, then increased by 28.3% to $1.1 billion in 2024, then tumbled by 150.55% to -$569.9 million in 2025.
  • Its last three reported values are -$569.9 million in Q3 2025, -$485.8 million for Q2 2025, and $1.0 billion during Q1 2025.